Scientific Publications & Presentations - Iovance Biotherapeutics

This site may contain information on an investigational agent(s) or investigational uses of approved agent(s) that has not been reviewed or approved by the FDA or other regulatory authorities. Iovance does not endorse or recommend any unapproved use of its products. Please refer to product prescribing information, where available.

Filter by year:

2025

Article

Long-term Efficacy and Safety of Lifileucel Tumor-infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Melanoma: A 5-year Analysis of the C-144-01 Study

Journal of Clinical Oncology

Medina T, et al

Presentation

Lifileucel in patients with advanced melanoma: 5-year outcomes of the C-144-01 study

ASCO 2025
May 30–June 3, 2025 Chicago, IL

Medina T, et al

Poster

Phase 2, multicenter study of the lifileucel regimen and pembrolizumab after frontline platinum-doublet chemotherapy and pembrolizumab in advanced non-small cell lung cancer

ASCO 2025
May 30–June 3, 2025 Chicago, IL

Creelan BC, et al

Poster

IOV-5001, autologous tumor-infiltrating lymphocytes armored with inducible membrane-tethered IL-12, shows enhanced antitumor efficacy with an improved cellular state

AACR 2025
April 25–30, 2025 Chicago, IL

Innamarato P, et al

Article

Tumor-Infiltrating Lymphocyte Cell Therapy for the Treatment of Advanced Melanoma: From Patient Identification to Posttreatment Management

Journal of the Advanced Practitioner in Oncology

Lisa Kottschade, et al

Presentation

Molecular Quantification and Tumor Reactivity Assessment of Tumor-infiltrating Lymphocytes Using Multiplexed Digital PCR

SSO 2025
March 27–29, 2025 Tampa, FL

Fadi El Rami, et al

Presentation

A multicenter phase 2 trial of lifileucel plus pembrolizumab in patients with checkpoint inhibitor–naive metastatic NSCLC: updated results

SITC Spring Scientific 2025
March 12–14, 2025 San Diego, CA

Adam Schoenfeld, et al

Poster

Multimodal single-cell sequencing analysis reveals putative tumor-reactive population in lifileucel TIL products

SITC Spring Scientific 2025
March 12–14, 2025 San Diego, CA

Joe Dean, et al

Poster

IOV-END-201: a phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes) in participants with previously treated advanced endometrial cancer

SGO 2025
March 14–17, 2025 Seattle, WA

Amir Jazaeri, et al

Poster

Superior anti-tumor activity of IL-12–engineered TIL (IOV-5001) in a simulated tumor microenvironment

MRA 2025
February 26–28, 2025 Washington, DC

Patrick Innamarato, et al

2024

Presentation

Multimodal single-cell sequencing analysis reveals putative tumor-reactive population in lifileucel TIL products

SITC 2024
November 6-10, 2024 Houston, TX

Joe Dean, et al

Poster

A multicenter phase 2 trial of lifileucel plus pembrolizumab in patients with checkpoint inhibitor-naive metastatic NSCLC: updated results

SITC 2024
November 6-10, 2024 Houston, TX

Benjamin C. Creelan, et al

Poster

Superior anti-tumor activity of IL12-engineered TIL IOV-5001 in simulated tumor microenvironment

SITC 2024
November 6-10, 2024 Houston, TX

Patrick Innamarato, et al

Poster

Manufacture and functional characterization of tumor-infiltrating lymphocyte product from endometrial tumors

IGCS 2024
October 16–18, 2024 Dublin, Ireland

Judy Fang, et al

Poster

Duration of cytopenias in patients with advanced melanoma receiving the lifileucel regimen: analysis of data from a phase 2 trial

SMR 2024
October 10-13, 2024 New Orleans, LA

Amod Sarnaik, et al

Poster

Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: updated results from IOV-COM-202 cohort 1A

SMR 2024
October 10-13, 2024 New Orleans, LA

Sajeve Thomas, et al

Poster

Tumor‑infiltrating lymphocytes with inducible membrane‑tethered IL‑12 cultured in optimized medium exhibit superior antitumor activity

ESMO 2024
September 13–17, 2024 Barcelona, Spain

Patrick Innamarato, et al

Presentation

Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: updated results from IOV-COM-202 Cohort 1A

ASCO 2024
May 31 – June 4, 2024 Chicago, IL

Sajeve Samuel Thomas, et al

Poster

IOV-3001, a modified interleukin-2 fusion protein, for potential use in tumor-infiltrating lymphocyte cell therapy regimens

ASCO 2024
May 31 – June 4, 2024 Chicago, IL

Michelle R. Simpson-Abelson, et al

Poster

Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients

ASCO 2024
May 31 – June 4, 2024 Chicago, IL

Amod Sarnaik, et al

Article

Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors

Cancer Discovery

Adam J. Schoenfeld, et al

Poster

TILVANCE-301, a Phase 3 Study of Lifileucel Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy in Combination With Pembrolizumab vs Pembrolizumab Alone in Treatment-Naive Unresectable or Metastatic Melanoma

AACR 2024
April 5-10, 2024 San Diego, CA

Sajeve Thomas, et al

Poster

Multimodal single-cell analysis of lifileucel tumor-infiltrating lymphocyte (TIL) product

AACR 2024
April 5-10, 2024 San Diego, CA

Joe Dean, et al

2023

Presentation

Long-Term Efficacy and Patterns of Response of Lifileucel Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Melanoma: A 4-Year Analysis of the C-144-01 Study

ESMO Immuno-Oncology Conference 2023
December 6-8, 2023 Geneva

Theresa Medina et al

Presentation

Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase 2 C-144-01 study

Society for Melanoma Research
November 6-9, 2023 Philadelphia

Harriet Kluger et al

Poster

TILVANCE-301, a phase 3 study of lifileucel tumor infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma

SITC 2023
November 1-5 San Diego

Daniel J Olson et al

Poster

Tumor infiltrating lymphocytes (TIL) with inducible and membrane-bound IL-12 exhibit superior antitumor activity in vitro

SITC 2023
November 1-5 San Diego

Yongliang Zhang et al

Poster

Long-term efficacy and safety of lifileucel tumor infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study

SITC 2023
November 1-5 San Diego

Theresa Medina et al

Presentation

Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase 2 C-144-01 study

ESMO Congress 2023
October 20-24, 2023 Madrid

Götz Ulrich Grigoleit et al

Poster

Successful generation of tumor-infiltrating lymphocytes (TIL) for adoptive cell therapy from mesothelioma

WCLC 2023
September 9–12, 2023 Singapore

Dean Fennell, et al

Presentation

Multicenter phase II trial of LN-145 TIL cell therapy plus pembrolizumab in patients with ICI-naïve metastatic NSCLC

WCLC 2023
September 9–12, 2023 Singapore

Adam Schoenfeld, et al

Poster

A novel expansion process enhances tumor-infiltrating lymphocyte (TIL) polyfunctionality, cytotoxicity, and expansion, while preserving cells in a less differentiated and more stem-like phenotype

ASCO 2023
June 2–6, 2023 Chicago, IL

Andrew Yuhas, et al

Poster

Trial in progress: A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma

ASCO 2023
June 2–6, 2023 Chicago, IL

Daniel Olson, et al

Poster + Supplement

Efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma enrolled in consecutive cohorts of the C-144-01 study

EBMT 2023
April 23–26, 2023 Paris, France

James Larkin, et al

Poster

Trial in progress: A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma

EADO 2023
April 20–22, 2023 Rome, Italy

James Larkin, et al

Poster

Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapy: Pooled analysis of consecutive cohorts (C‑144‑01 study)

HOPA 2023
March 29–April 1, 2023 Phoenix, AZ

Amod Sarnaik, et al

Poster

Immune checkpoint inhibitor (ICI) treatment after progression on anti–PD-1 therapy in advanced melanoma: A systematic review of the literature

NCCN Annual Conference 2023
March 31–April 2, 2023 Orlando, FL

Daniel Olson, et al

Presentation

Lifileucel TIL cell therapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: Tumor tissue procurement data from the C-144-01 study

Society of Surgical Oncology 2023
March 22–25, 2023 Boston, MA

Michael E. Egger, et al

Presentation

Lifileucel TIL cell therapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: Tumor tissue procurement data from the C-144-01 study

Society of Surgical Oncology Advanced Cancer Therapies 2023
February 18–20, 2023 San Diego, CA

Michael E. Egger, et al

Poster

Response to lifileucel tumor‑infiltrating lymphocyte (TIL) cell therapy after ICI resistance regardless of definition: An analysis of the C‑144‑01 trial in patients with advanced melanoma

Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ & CIBMTR® 2023
February 15–19, 2023 Orlando, FL

Amod Sarnaik, et al

2022

Article

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: Pooled analysis of consecutive cohorts of the C-144-01 study

Journal for ImmunoTherapy of Cancer

Jason Alan Chesney, MD, PhD, et al.

Presentation

Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte (TIL) cell therapy: Post hoc analysis of the C-144-01 trial of lifileucel in patients with advanced melanoma

ESMO Immuno-Oncology Congress
December 7-9, 2022 Geneva, Switzerland

Jessica C. Hassel, et al

Presentation

Lifileucel, an autologous tumor-infiltrating lymphocyte (TIL) cell monotherapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: Pooled analysis of consecutive cohorts (C-144-01 study)

Melanoma Bridge
December 1–3 2022 Naples, Italy

Omid Hamid, et al

Presentation

Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: Pooled analysis of consecutive cohorts (C-144-01 study)

SITC Annual Meeting
November 8-12, 2022 Boston, MA and Virtually

Amod Sarnaik, et al.

Poster

Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: Pooled analysis of consecutive cohorts (C-144-01 study)

SITC Annual Meeting
November 8-12, 2022 Boston, MA and Virtually

Amod Sarnaik, et al.

Poster

Trial in progress: A phase 1/2 open-label study (IOV-GM1-201) of TALEN-mediated PD-1–inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC

SITC Annual Meeting
November 8-12, 2022 Boston, MA and Virtually

Allison Betof Warner, et al.

Poster

Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody

ESMO Congress 2022
September 9 – 13, 2022 Paris, France

James Larkin, et al.

Poster

A phase 1/2 open-label study (IOV-GM1-201) of TALEN ®-mediated PD-1 inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC

ESMO Congress 2022
September 9 – 13, 2022 Paris, France

Jason Chesney, et al.

Article

Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy

The Cancer Journal
https://journals.lww.com/journalppo/Fulltext/2022/07000/Surgical_Considerations_for_Tumor_Tissue.6.aspx

John E. Mullinax, MD, et al.

Poster

Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naïve and -experienced patients with metastatic melanoma treated with lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy

ASCO Annual Meeting
June 3-7, 2022 Chicago, IL and Virtually

Harriet Kluger, MD, et al.

Poster

Trial in progress: A phase 2 multicenter study (IOV-LUN-202) of autologous tumor-infiltrating lymphocyte (TIL) cell therapy (LN-145) in patients with metastatic non-small cell lung cancer (mNSCLC)

AACR Annual Meeting
April 8-13, 2022 New Orleans, LA and Virtually

Jason Alan Chesney, MD, PhD, et al.

Poster

Preclinical activity and manufacturing feasibility of genetically modified PDCD-1 knockout (KO) tumor infiltrating lymphocyte (TIL) cell therapy

AACR Annual Meeting
April 8-13, 2022 New Orleans, LA and Virtually

Arvind Natarajan, PhD, et al.

Poster

Successful Manufacturing of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy from Cryopreserved Melanoma Tumors Shipped from Australia

ASTCT/CIBMTR Tandem Meetings
April 23-26, 2022 Salt Lake City, UT and Virtually

Kenneth Onimus, et al.

Poster

Decitabine Treatment of Tumor-Infiltrating Lymphocytes (TIL) during Ex Vivo Expansion Induces a More Memory-like Phenotype, Reduces Inhibitory Receptor Expression, and Increases Functionality

ASTCT/CIBMTR Tandem Meetings
April 23-26, 2022 Salt Lake City, UT and Virtually

Rafael Cubas, PhD, et al.

2021

Poster

Trial in progress: Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001, an Autologous, Non-Genetically Modified, Polyclonal T-cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (IOV-CLL-01)

ASH Annual Meeting
Dec. 11-14, 2021 Atlanta, GA and Virtually

Javier Pinilla-Ibarz, et al.

Poster

AKT inhibition during ex vivo TIL expansion enhances cytokine production and function while increasing the population of less differentiated (CD39-CD69-) CD8+ T-cells

ESMO Immuno-Oncology Annual Meeting
Dec. 8-11, 2021 Geneva, Switzerland

Rafael Cubas, PhD, et al.

Presentation

Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers

SITC Annual Meeting
Nov. 12-14, 2021 Washington, DC and Virtually

David O’Malley, MD, et al.

Poster

First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC)

SITC Annual Meeting
Nov. 12-14, 2021 Washington, DC and Virtually

Adam J Schoenfeld, MD, et al.

Poster

Successful generation of tumor-infiltrating lymphocyte (TIL) product from renal cell carcinoma (RCC) tumors for adoptive cell therapy

SITC Annual Meeting
Nov. 12-14, 2021 Washington, DC and Virtually

Brian Halbert, MD, MPH, et al.

Poster

Expansion of tumor-infiltrating lymphocytes (TIL) using static bag for the clinical manufacturing rapid expansion protocol (REP) process

SITC Annual Meeting
Nov. 12-14, 2021 Washington, DC and Virtually

Kenneth Onimus, et al.

Presentation

Trial in progress: A Phase 2, multicenter study of autologous tumor-infiltrating lymphocyte (TIL, LN-145) cell therapy in patients with metastatic non-small cell lung cancer (IOV-LUN-202)

IASLC 2021 World Conference on Lung Cancer
Sept. 8-14, 2021 Virtual Meeting

Erminia Massarelli, MD, MS, PhD, et al.

Presentation

Trial in progress: A Phase 2, multicenter study of autologous tumor-infiltrating lymphocytes (TIL, lifileucel [LN-144], LN-145, LN-145-S1) in patients with solid tumors (IOV-COM-202)

IASLC 2021 World Conference on Lung Cancer
Sept. 8-14, 2021 Virtual Meeting

Scott Gettinger, MD, et al.

Presentation

Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy

ASCO Annual Meeting
June 4-8, 2021 Virtual Meeting

James M. G. Larkin, MD, PhD, et al.

Presentation

Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma

ASCO Annual Meeting
June 4-8, 2021 Virtual Meeting

Sajeve Samuel Thomas, et al.

Article

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

Journal of Clinical Oncology 2021;39(24):2656-2666.| DOI: 10.1200/JCO.21.00612 Available at
https://ascopubs.org/doi/full/10.1200/JCO.21.00612.

Amod A. Sarnaik, MD; Omid Hamid, MD; Nikhil I. Khushalani, MD; Karl D. Lewis, MD; Theresa Medina, MD; Harriet M. Kluger, MD; Sajeve S. Thomas, MD; Evidio Domingo-Musibay, MD; Anna C. Pavlick, DO, MBA; Eric D. Whitman, MD; Salvador Martin-Algarra, MD, PhD; Pippa Corrie, PhD; Brendan D. Curti, MD; Judit Oláh, MD, DSc; Jose Lutzky, MD; Jeffrey S. Weber, MD, PhD; James M. G. Larkin, MD, PhD; Wen Shi, MD, PhD; Toshimi Takamura, BA, BS; Madan Jagasia, MD; Harry Qin, PhD; Xiao Wu, PhD; Cecile Chartier, PhD; Friedrich Graf Finckenstein, MD; Maria Fardis, PhD, MBA; John M. Kirkwood, MD; and Jason A. Chesney, MD, PhD

Presentation

Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced (unresectable or metastatic) melanoma: durable duration of response at 28 month follow-up

AACR Annual Meeting
April 10-15, 2021 Virtual Meeting

Jason Alan Chesney, MD, PhD, et al.

Poster

Trial in progress: A Phase 2, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN-145) cell therapy in patients with metastatic non-small cell lung cancer (IOV-LUN-202)

AACR Annual Meeting
Apr. 10-15, 2021 Virtual Meeting

Erminia Massarelli, MD, PhD, et al.

Poster

Trial in progress: A Phase 2, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145/LN-145-S1) in patients with solid tumors (IOV-COM-202)

AACR Annual Meeting
Apr. 10-15, 2021 Virtual Meeting

Scott Gettinger, MD, et al.

Poster

Trial in progress: A Phase 1/2 study evaluating the safety and efficacy of IOV-2001 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (IOV-CLL-01)

AACR Annual Meeting
Apr. 10-15, 2021 Virtual Meeting

Meixiao Long, MD, PhD, et al.

2020

Poster

Safety and efficacy of tumor infiltrating lymphocytes (TIL; LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC

SITC Annual Meeting
Nov. 9-14, 2020 Virtual Meeting

Antonio Jimeno, Sophie Papa, Missak Haigentz, Juan F. Rodriguez-Moreno, Julian Schardt, Maria Fardis, Friedrich Graf Finckenstein, Rana Fiaz, Guang Chen, Alex Cacovean, Zelanna Goldberg, Ammar Sukari

Poster

In vivo persistence of Iovance tumor-infiltrating lymphocytes LN-145 in cervical cancer patients

ESMO Congress
Sept. 19-21, 2020 Virtual Meeting

Amir Jazaeri, Viktoria Gontcharova, Michelle Blaskovich, Kranthi Kunkalla, Emma Masteller, Maria Fardis, Cécile Chartier

Poster

Genetic Modification of Iovance’s TIL through TALEN-mediated knockout of PD-1 as a strategy to empower TIL therapy for cancer

ESMO Congress
Sept. 19-21, 2020 Virtual Meeting

Krit Ritthipichai, Marcus Machin, Shwetha Lakshmipathi, Alexandre Juillerat, Laurent Poirot, Maria Fardis, Cécile Chartier

Poster

Iovance Generation-2 Tumor-infiltrating Lymphocyte (TIL) Product is Reinvigorated During the Manufacturing Process

ESMO Congress
Sept. 19-21, 2020 Virtual Meeting

Michelle R. Simpson-Abelson, Angel Cedano-Hilton, Kenneth D’Arigo, Maria Fardis, Cécile Chartier

Article

Expert Insight – Current and future directions for tumor infiltrating lymphocyte therapy for the treatment of solid tumors

Cell & Gene Therapy Insights. 2020;6(6):855-863. DOI: 10.18609/cgti.2020.088

Maria Fardis, Kelly DiTrapani, Cécile Chartier, Friedrich Graf Finckenstein

Presentation

Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies

ASCO Annual Meeting
May 29-30, 2020 Virtual Meeting

Amod Sarnaik, MD, H. Lee Moffitt Cancer Center, Tampa, FL

2019

Poster

Lifileucel, a Potential Therapy for Metastatic Melanoma Patients who are Primary Refractory to Prior Anti-PD-1 Therapy

SMR Annual Meeting
November 20-23, 2019 Salt Lake City

Amod Sarnaik, Nikhil I. Khushalani, Jason Alan Chesney, Harriet M. Kluger, Karl D. Lewis, Theresa Medina, Evidio Domingo-Musibay, Anna C. Pavlick, Eric D. Whitman, Salvador Algarra, Pippa Corrie, Omid Hamid, Jose Lutzky, Judit Oláh, Jeffrey S. Weber, James M. G. Larkin, Wen Shi, Kelly DiTrapani, Harry Qin, Renee Wu, Friedrich Graf Finckenstein, Maria Fardis, John M. Kirkwood

Poster

Iovance Gen 2 TIL Manufacturing Process Produces Drug Products that Exhibit Favorable Quality Attributes for Adoptive Cell Transfer Across 5 Solid Tumor Indications

SITC Annual Meeting
November 6-10, 2019 National Harbor, MD

Seth Wardell, Maritza Lienlaf-Moreno, Michelle Blaskovich, Ian Frank, Virginia Van Grod, Maria Fardis and Joseph Wypych

Poster

Safety and efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update

SITC Annual Meeting
November 6-10, 2019 National Harbor, MD

Amod Sarnaik, Nikhil I. Khushalani, Jason Alan Chesney, Harriet M. Kluger, Brendan D. Curti, Karl D. Lewis, Theresa Medina, Sajeve Samuel Thomas, Anna C. Pavlick, Eric D. Whitman, Salvador Algarra, Pippa Corrie, Omid Hamid, Jose Lutzky, Judit Oláh, DSc, Jeffrey S. Weber, James M. G. Larkin, Wen Shi, Kelly DiTrapani, Harry Qin, Mariam Mirgoli, Renee Wu, Toshimi Takamura, Maria Fardis, John M. Kirkwood

Poster

Expanding Iovance’s tumor infiltrating lymphocytes (TIL) from core biopsies for adoptive T cell therapy using a 22-day manufacturing process

SITC Annual Meeting
November 6-10, 2019 National Harbor, MD

Michelle R. Simpson-Abelson, Angel Hilton, Kenneth D’Arigo, Maria Fardis, and Cécile Chartier

Poster

Silencing PD-1 using PH-762 (PD-1 targeting INTASYL compound) to improve Iovance TIL effector function using Gen 2 manufacturing method

SITC Annual Meeting
November 6-10, 2019 National Harbor, MD

Inbar Azoulay Alfaguter, Michelle Simpson-Abelson, Krit Ritthipichai, Kenneth D’Arigo, Florangel Hilton, Marcus Machin, Dingxue Yan, James Cardia, Maria Fardis, and Cécile Chartier

Poster

Iovance Peripheral Blood Lymphocytes (PBL): A Potential Cell Therapy Strategy For The Treatment of Chronic Lymphocytic Leukemia

European Hematologic Association Annual Congress
June 13-16, 2019 Amsterdam

Lavakumar Karyampudi, Michelle Blaskovich, Ian Frank, Nermin Gerges, Amanda Stramer, Arvind Natarajan, Meixiao Long, Cecile Chartier, John Byrd, Maria Fardis

Poster

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1

ASCO Annual Meeting
May 31-June 4, 2019 Chicago

Amod Sarnaik, Nikhil I. Khushalani, Jason Alan Chesney, Harriet M. Kluger, Brendan D. Curti, Karl D. Lewis, Sajeve Samuel Thomas, Eric D. Whitman, Omid Hamid, Jose Lutzky, Anna C. Pavlick, Jeffrey S. Weber, James M.G. Larkin, Debora Barton, Kelly DiTrapani, Renee Wu, Maria Fardis, John M. Kirkwood

Poster

Safety & efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma

ASCO Annual Meeting
May 31-June 4, 2019 Chicago

Amir A. Jazaeri, Emese Zsiros, Rodabe Navroze Amaria, Andrew S. Artz, Robert P. Edwards, Robert Michael Wenham, Brian M. Slomovitz, Axel Walther, Sajeve Samuel Thomas, Jason Alan Chesney, Robert Morris, Koji Matsuo, Stephanie Gaillard, Peter G. Rose, Jesus Garcia Donas, Jacqueline Maria Tromp, Kelly DiTrapani, Huiling Li, Maria Fardis, Bradley J. Monk

Poster

A Phase 2 study of autologous tumor infiltrating lymphocytes (TIL; lifileucel [LN-144]/LN-145) in patients with solid tumors

ASCO Annual Meeting
May 31-June 4, 2019 Chicago

Jason Chesney, Jose Lutzky, Sajeve Samuel Thomas, Jorge Nieva, Eva Muñoz Couselo, Juan Francisco Moreno Rodriguez, Juan Jesus Martin-Liberal, Alex Cacovean, Huiling Li, Zelanna Goldberg, Maria Fardis, Scott Gettinger

Poster

Expansion of tumor-infiltrating lymphocytes (TIL) using Iovance’s Gen 2 process from bladder cancer for adoptive immunotherapy

AACR Meeting – Bladder Cancer: Transforming the Field
May 18-21, 2019 Denver

Qiang John Li, Khurshid Guru, Amit Lugade, Elizabeth Brese, Kunle Odunsi, Anand Veerapathran, Kenneth Onimus, Adrian Wells, Cécile Chartier, Arvind Natarajan, Maria Fardis, Gurkamal Chatta

Poster

Persistence of cryopreserved tumor-infiltrating lymphocyte product lifileucel (LN-144) in C-144-01 study of advanced metastatic melanoma

AACR Annual Meeting
March 29-April 03, 2019 Atlanta

Viktoria Gontcharova, Sam Suzuki, Michelle Abelson, Michelle Blaskovich, Cécile Chartier

Poster

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients following progression on checkpoint inhibitors

ASCO-SITC Clinical Immuno-Oncology Symposium
February 28-March 02, 2019 San Francisco

Amod Sarnaik, Sajeve Samuel Thomas, Diwakar Davar, John M. Kirkwood, Harriet Kluger, Jose Lutzky, Melissa Wilson, Anna C. Pavlick, Brendan Curti, Eric Whitman, Karl Lewis, Giao Phan, Omid Hamid, Evidio Domingo-Musibay, Marc Ernstoff, Hendrik-Tobias Arkenau, Judit Olah, Pippa Corrie, Stéphane Dalle, Salvador Algarra, Gregory Daniels, Lavakumar Karyampudi, Toshimi Takamura, Debora Barton, Sam Suzuki, Nancy L. Samberg, Maria Fardis, Jason Chesney

2018

Poster

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients following progression on checkpoint inhibitors

SITC Annual Meeting
November 9-11, 2018 Washington, DC

Amod Sarnaik, Sajeve Samuel Thomas, Diwakar Davar, John M. Kirkwood, Harriet Kluger, Jose Lutzky, Melissa Wilson, Anna C. Pavlick, Brendan Curti, Eric Whitman, Karl Lewis, Giao Phan, Omid Hamid, Evidio Domingo-Musibay, Marc Ernstoff, Hendrik-Tobias Arkenau, Judit Olah, Pippa Corrie, Stéphane Dalle, Salvador Algarra, Gregory Daniels, Lavakumar Karyampudi, Toshimi Takamura, Debora Barton, Sam Suzuki, Nancy L. Samberg, Maria Fardis, Jason Chesney

Poster

PD1-positive tumor-infiltrating lymphocytes (TIL) for the next generation of adoptive T cell therapy

SITC Annual Meeting
November 9-11, 2018 Washington, DC

Michelle R. Simpson-Abelson, Kenneth D’Arigo, Angel Cedano-Hilton, Ian Frank, Viktoria Gontcharova, Krit Ritthipichai, and Cécile Chartier

Poster

A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma

ASCO Annual Meeting
June 1-5, 2018 Chicago

Amod Sarnaik, Brendan Curti, Diwakar Davar, John M. Kirkwood, Omid Hamid, Jose Lutzky, Melissa Wilson, Harriet Kluger, Eric Whitman , Giao Phan, Sajeve Samuel Thomas, Karl Lewis, Hendrik-Tobias Arkenau, Bente Larsen, Igor Gorbatchevsky, Corina Andresen, Sam Suzuki, Nancy Samberg, Maria Fardis, Jason Chesney

Poster

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) for the Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

ASCO Annual Meeting
June 1-5, 2018 Chicago, IL

Rom Leidner, Ammar Sukari, Christine Chung, James Ohr, Missak Haigentz, Ezra E. W. Cohen, Robert J. Brown, Igor Gorbatchevsky, Sam Suzuki, Maria Fardis, Robert L. Ferris

Poster

Trial in Progress: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma 

ASCO Annual Meeting
June 1-5, 2018 Chicago

Amir Jazaeri, Robert Edwards, Robert Wenham, Koji Matsuo, Gini F. Fleming, David M. O’Malley, Brian Slomovitz, Bradley Monk, Robert J. Brown, Igor Gorbatchevsky, Sam Suzuki, Maria Fardis, Emese Zsiros, MD

Poster

Trial in Progress: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma

AACR Annual Meeting
April 14-18 Chicago

Amir Jazaeri, Robert Edwards, Robert Wenham, Koji Matsuo, Gini F. Fleming, David M. O’Malley, Brian Slomovitz, Bradley Monk, Robert J. Brown, Igor Gorbatchevsky, Sam Suzuki, Maria Fardis, Emese Zsiros, MD

Poster

Phase 2 Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combination with Anti-PD-L1 Inhibitor Durvalumab (MEDI4736) in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

AACR Annual Meeting
April 14-18, 2018 Chicago

Sylvia Lee, Liza Villaruz, Susie Tanamly, Igor Gorbatchevsky, Sam Suzuki, Maria Fardis, Missak Haigentz

Poster

Activating OX40 receptor promotes the expression of CD8+ TIL with enhanced T-cell Effector Function

AACR Annual Meeting
April 14-18, 2018 Chicago

Krit Ritthipichai, Marcus Machin, Maria Fardis, and Cecile Chartier

2017

Poster

Novel Cryopreserved Tumor Infiltrating Lymphocytes (LN-144) Administered to Patients with Metastatic Melanoma Demonstrates Efficacy and Tolerability in a Multicenter Phase 2 Clinical Trial

SITC Annual Meeting
November 8, 2017 National Harbor, MD

Amod Sarnaik, Jason Chesney, Harriet Kluger, Brendan Curti, Omid Hamid, Jose Lutzky, Maria Fardis, Igor Gorbatchevsky, Sam Suzuki, Bente Larsen, Nancy L. Samberg, John Kirkwood

Poster

A Cryopreserved Tumor Infiltrating Lymphocyte (TIL) Product for LN-144, Generated with an Abbreviated Method Suitable for High Throughput Commercial Manufacturing Exhibits Favorable Quality Attributes For Adoptive Cell Transfer

SITC Annual Meeting
November 8, 2017 National Harbor, MD

Seth Wardell, Ian Frank, Lavakumar Karyampudi, Anand Veerapathran, Michelle Simpson-Abelson, Maritza Lienlaf Moreno, Michelle Blaskovich, Joseph Wypych, and Maria Fardis

Poster

Studies of Key Quality Attributes for TIL Product, LN-144

SITC Annual Meeting
November 8, 2017 National Harbor, MD

Krit Ritthipichai, Ian Frank, Marcus Machin, Michelle Blaskovich, Amanda Stramer, Michelle Simpson-Abelson, Maria Fardis, Cecile Chartier

Poster

A phase 2 study to evaluate the safety and efficacy of using autologous tumor infiltrating lymphocytes (LN -145) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

SITC Annual Meeting
November 8, 2017 National Harbor, MD

Leidner R, Ohr J, Chung C, Brown RJ, Suzuki S, Gorbatchevsky I, Fardis M, and Ferris RL

Poster

A phase 2, multicenter study to evaluate the efficacy and safety of using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma

SITC Annual Meeting
November 8, 2017 National Harbor, MD

Amir Jazaeri, Robert Edwards, Emese Zsiros, Robert Brown, Igor Gorbatchevsky, Sam Suzuki, Maria Fardis, Robert Wenham

Poster

The T-cell Growth Factor Cocktail IL-2/IL-15/IL-21 Enhances Expansion and Effector Function of Tumor-Infiltrating T cells in a Novel Process Developed by Iovance

SITC Annual Meeting
November 8, 2017 National Harbor, MD

Michelle R. Simpson-Abelson, Christopher Mosychuk, Ian Frank, Krit Ritthipichai, and Cecile Chartier

Poster

Phenotypic and Functional Characterization of Tumor Infiltrating Lymphocytes (TIL) Grown from Non-Hodgkin Lymphoma Tumors – Implications for the Development of Novel Therapies for Lymphoma

ESMO Annual Meeting
September 7-12, 2017 Madrid

Lavakumar Karyampudi, Aishwarya Gokuladass, Michelle Blaskovich, Maria Fardis, Michael T Lotze

Poster

Efficacy of Single Administration of Tumor Infiltrating Lymphocytes (TIL) in Heavily Pre-Treated Metastatic Melanoma Patients Following Checkpoint Therapy

ASCO Annual Meeting
June 2-6, 2017 Chicago

Amod Sarnaik, Harriet Kluger, Jason Chesney, Jyothi Sethuraman, Michael T. Lotze, Bente Larsen, Igor Gorbatchevsky, Nancy L. Samberg, Sam Suzuki, Lei Wang, Mariam Mirgoli, Maria Fardis, Brendan Curti

Poster

K+ Channel Activation Promotes Tumor Infiltrating Lymphocyte (TIL) Expansion and Enhances Expression of CCR7

AAI Annual Meeting
May 12-16, 2017 Washington, DC

Krit Ritthipichai, Marcus Machin, Michelle Simpson-Abelson, Christopher Mosychuk, Anand Veerapathran, and Michael T. Lotze

Poster

Emigrant Tumor Infiltrating Lymphocytes (TIL) Profoundly Differ from Remnant T-cells

AACR Annual Meeting
April 1-5, 2017 Washington, DC

Michelle R. Simpson-Abelson, Christopher Mosychuk, Maria Fardis, and Michael T. Lotze

2016

Poster

Redirected lysis assay as an efficient potency assay to assess TILs for immunotherapy

Journal for ImmunoTherapy of Cancer 2016;4(suppl 1):82. DOI: 10.1186/s40425-016-0172-7

Aishwarya Gokuldass, Michelle A Blaskovich, Charlene Kopits, Brian Rabinovich, Michael T. Lotze

Poster

Remarkably Stable Tumor-Infiltrating Lymphocytes (TIL) for Infusion Phenotype Following Cryopreservation

Journal for ImmunoTherapy of Cancer 2016;4(suppl 1):82. DOI: 10.1186/s40425-016-0172-7

Ian Frank, Amanda Stramer, Michelle A Blaskovich, Seth Wardell, Maria Fardis, James Bender, Michael T Lotze

Poster

Successful expansion and characterization of tumor infiltrating lymphocytes (TILs) from non-melanoma tumors

Journal for ImmunoTherapy of Cancer 2016;4(suppl 1):82. DOI: 10.1186/s40425-016-0172-7

Jyothi Sethuraman, Laurelis Santiago, Jie Qing Chen, Zhimin Dai, Seth Wardell, James Bender, Michael T Lotze

Poster

Artificial antigen presenting cells promote expansion of tumor-infiltrating lymphocytes (TILs)

Journal for ImmunoTherapy of Cancer 2016;4(suppl 1):82. DOI: 10.1186/s40425-016-0172-7

Anandaraman Veerapathran, Aishwarya Gokuldass, Amanda Stramer, Jyothi Sethuraman, Michelle A Blaskovich, Doris Wiener, Ian Frank, Laurelis Santiago, Brian Rabinovich, Maria Fardis, James Bender, Michael T Lotze

Article

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma

Journal of Clinical Oncology 2016;34(20):2389-2397. DOI: 10.1200/JCO.2016.66.7220

Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US, Klebanoff CA, Hughes MS, Restifo NP, Langhan MM, Shelton TE, Lu L, Kwong MLM, Ilyas S, Klemen ND, Payabyab EC, Morton KE, Toomey MA, Steinberg SM, White DE, and Rosenberg SA

2015

Article

Adoptive cell transfer as personalized immunotherapy for human cancer

Science 03 Apr 2015, Vol. 348, Issue 6230, pp. 62-68, DOI 10.1126/science.aaa4967

Rosenberg SA, and Restifo NP

Article

Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.

Clin Cancer Res. 2015;21(3):611-21

Chacon JA, Sarnaik AA, Chen JQ, et al.

2014

Article

Finding suitable targets is the major obstacle to cancer gene therapy

Cancer Gene Ther. 2014;21(2):45-47

Rosenberg SA

Article

Exploiting the curative potential of adoptive T-cell therapy for cancer

Immunol Rev. 2014;257(1):56-71

Hinrichs CS, Rosenberg SA

Explore Our Clinical Pipeline